Using in vitro treatment of recombinant IL-22 at a concentration similar to our own study of 10 ng/mL, Radaeva et al.[27] were able to promote cell growth and survival of human hepatocellular carcinoma HepG2 cells via the activation of a series of anti-apoptotic and mitogenic proteins which included: Bcl-2, Bcl-xL, Mcl-1, c-myc, and cyclin D1. Here, IL22 is linked to hepatocellular carcinoma.